full

 – Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) – – 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of <55 mg/dL compared to 0% of Patients Treated…

AYER, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- AMSC (Nasdaq: AMSC), a leading system provider of megawatt-scale power resiliency solutions that orchestrate the rhythm and harmony of power on the grid™, and that protect and expand the…

CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental…

Full Year 2022 total revenues with double-digit growth of 12% at…

SINGAPORE, May 05, 2023 (GLOBE NEWSWIRE) -- Genius Group…

 Audited full year 2022 annual financial figures due to be…

ARLINGTON, Va., May 01, 2023 (GLOBE NEWSWIRE) -- Edge Total…

WISeKey…

- Net revenues grow 48% to All-Time High of US$48.2 million…

Pivotal Phase 3 trial NANORAY-312 ongoing globally with 104 sites…